Automated insulin delivery use in a woman living with type 1 diabetes on peritoneal dialysis: a case report

Automated insulin delivery (AID) is the gold standard of treatment for type 1 diabetes mellitus (T1DM). However, little data on the use in people on peritoneal dialysis (PD) exist. To share real-world experience on the use of AID (Medtronic MiniMed 780G SmartGuard and Guardian 4 continuous glucose monitoring system) in a woman living with type 1 diabetes on PD, we report the implementation despite the complex setting of type 1 diabetes with multiple diabetes-associated complications, PD, visual impairment, and a complete language barrier. Glycemic control 14 days before the start of AID on multiple daily injections and 9 months after the conversion is presented. AID might be a safe and promising therapeutic option for individuals with T1DM and end-stage kidney disease requiring PD. Further research is needed to demonstrate both safety and efficacy in this special population, and assessment of patient-reported outcome measures.